Skip to main content Accessibility help
×
Home
  • Print publication year: 2013
  • Online publication date: February 2015

24 - 14-3-3 proteins in cancer

from Part 2.1 - Molecular pathways underlying carcinogenesis: signal transduction

Summary

Introduction

14-3-3 proteins constitute a family of acidic α-helical cup-shaped dimers that are ubiquitously expressed in all eukaryotic cells. Well over 200 proteins have been identified as 14-3-3-binding ligands, and many of these proteins have established roles in cell-cycle control, DNA damage responses, growth-factor receptor signaling, regulation of gene expression, metabolism, and apoptosis (1–5; Figure 24.1). Early work that hinted at a connection between protein phosphorylation and 14-3-3 binding came from work on tryptophan hydroxylase (6), an enzyme involved in neurotransmitter biosynthesis, and Raf, the upstream activator of the classical MAP kinase pathway (7). Work from the Shaw lab (8), building on detailed phosphorylation studies of Raf by Debbie Morrison's group, revealed that 14-3-3 proteins specifically bound to phosphoserine-containing sequences. That work, together with oriented peptide library screening on all mammalian 14-3-3 proteins by Yaffe and colleagues (9), led to the identification of two optimal phosphoserine/threonine-containing motifs – RSx[pS/pT]xP (mode-1) and Rxxx[pS/pT]xP (mode-2) – that are recognized by all 14-3-3 isotypes (9). Pro in the pS/pT+2 position is not absolutely required (9–11), and an additional motif (mode-3) has been found in proteins where the pS/pT residue is the final or next to the last residue at the C-terminus (12). Although there are clear examples of proteins and peptides that differ from these motifs, or that do not require phosphorylation at all for binding, most 14-3-3 ligands use phosphorylated sequences that closely resemble the optimal 14-3-3 consensus motifs for binding. This ability of 14-3-3 proteins to bind to large numbers of ligands in a phospho-regulated manner provides a mechanism for cytoplasmic Ser/Thr kinases, including kinases that are misregulated in cancer, such as mTor, AKT, and PKC family members, to broadly exert control over many key signaling events required for tumor cell survival.

References
Fu, H, Subramanian, RR, Masters, SC. 14-3-3 proteins: structure, function, and regulation. Annual Review of Pharmacology and Toxicology 2000;40:617–47.
Jin, J, Smith, FD, Stark, C, et al. Proteomic, functional, and domain-based analysis of in vivo 14-3-3 binding proteins involved in cytoskeletal regulation and cellular organization. Current Biology 2004;14:1436–50.
Meek, SE, Lane, WS, Piwnica-Worms, H. Comprehensive proteomic analysis of interphase and mitotic 14-3-3-binding proteins. Journal of Biological Chemistry 2004;279:32 046–54.
Pozuelo Rubio, M, Geraghty, KM, Wong, BH, et al. 14-3-3-affinity purification of over 200 human phosphoproteins reveals new links to regulation of cellular metabolism, proliferation and trafficking. Biochemical Journal 2004;379:395–408.
van Heusden, GP. 14-3-3 proteins: regulators of numerous eukaryotic proteins. IUBMB Life 2005;57:623–9.
Furukawa, Y, Ikuta, N, Omata, S, et al. Demonstration of the phosphorylation-dependent interaction of tryptophan hydroxylase with the 14-3-3 protein. Biochemical and Biophysical Research Communications 1993;194:144–9.
Michaud, NR, Fabian, JR, Mathes, KD, Morrison, DK. 14-3-3 is not essential for Raf-1 function: identification of Raf-1 proteins that are biologically activated in a 14-3-3- and Ras-independent manner. Molecular and Cellular Biology 1995;15:3390–7.
Muslin, AJ, Tanner, JW, Allen, PM, Shaw, AS. Interaction of 14-3-3 with signaling proteins is mediated by the recognition of phosphoserine. Cell 1996;84:889–97.
Yaffe, MB, Rittinger, K, Volinia, S, et al. The structural basis for 14–3–3: phosphopeptide binding specificity. Cell 1997;91:961–71.
Rittinger, K, Budman, J, Xu, J, et al. Structural analysis of 14-3-3 phosphopeptide complexes identifies a dual role for the nuclear export signal of 14-3-3 in ligand binding. Molecular Cell 1999;4:153–66.
Johnson, C, Crowther, S, Stafford, MJ, et al. Bioinformatic and experimental survey of 14–3–3-binding sites. Biochemical Journal; 2010:69–78.
Coblitz, B, Shikano, S, Wu, M, et al. C-terminal recognition by 14-3-3 proteins for surface expression of membrane receptors. Journal of Biological Chemistry 2005;280:36 263–72.
Wang, W, Shakes, DC. Molecular evolution of the 14-3-3 protein family. Journal of Molecular Evolution 1996;43:384–98.
Rosenquist, M, Alsterfjord, M, Larsson, C, Sommarin, M. Data mining the Arabidopsis genome reveals fifteen 14-3-3 genes: expression is demonstrated for two out of five novel genes. Plant Physiology 2001;127:142–9.
Vincenz, C, Dixit, VM. 14-3-3 proteins associate with A20 in an isoform-specific manner and function both as chaperone and adapter molecules. Journal of Biological Chemistry 1996;271:20 029–34.
Mils, V, Baldin, V, Goubin, F, et al. Specific interaction between 14-3-3 isoforms and the human CDC25B phosphatase. Oncogene 2000;19:1257–65.
Dalal, SN, Yaffe, MB, DeCaprio, JA. 14-3-3 family members act coordinately to regulate mitotic progression. Cell Cycle 2004;3:672–7.
Jagemann, LR, Perez-Rivas, LG, Ruiz, EJ, et al. The functional interaction of 14-3-3 proteins with the ERK1/2 scaffold KSR1 occurs in an isoform-specific manner. Journal of Biological Chemistry 2008;283:17 450–62.
Hermeking, H. The 14-3-3 cancer connection. Nature Reviews Cancer 2003;3:931–43.
Aitken, A. Functional specificity in 14-3-3 isoform interactions through dimer formation and phosphorylation: chromosome location of mammalian isoforms and variants. Plant Molecular Biology 2002;50:993–1010.
Wilker, EW, Grant, RA, Artim, SC, Yaffe, MB. A structural basis for 14–3–3sigma functional specificity. Journal of Biological Chemistry 2005;280:18 891–8.
Chaudhri, M, Scarabel, M, Aitken, A. Mammalian and yeast 14-3-3 isoforms form distinct patterns of dimers in vivo. Biochemical and Biophysical Research Communications 2003;300:679–85.
Benzinger, A, Muster, N, Koch, HB, Yates, JR, Hermeking, H. Targeted proteomic analysis of 14-3-3 sigma, a p53 effector commonly silenced in cancer. Molecular Cell Proteomics 2005;4:785–95.
Gardino, AK, Smerdon, SJ, Yaffe, MB. Structural determinants of 14-3-3 binding specificities and regulation of subcellular localization of 14–3–3-ligand complexes: a comparison of the X-ray crystal structures of all human 14-3-3 isoforms. Seminars in Cancer Biology 2006;16:173–82.
Rosenquist, M, Sehnke, P, Ferl, RJ, Sommarin, M, Larsson, C. Evolution of the 14-3-3 protein family: does the large number of isoforms in multicellular organisms reflect functional specificity?Journal of Molecular Evolution 2000;51:446–58.
Yang, X, Lee, WH, Sobott, F, et al. Structural basis for protein-protein interactions in the 14-3-3 protein family. Proceedings of the National Academy of Sciences USA 2006;103:17 237–42.
Xiao, B, Smerdon, SJ, Jones, DH, et al. Structure of a 14-3-3 protein and implications for coordination of multiple signalling pathways. Nature 1995;376:188–91.
Liu, D, Bienkowska, J, Petosa, C, et al. Crystal structure of the zeta isoform of the 14-3-3 protein. Nature 1995;376:191–4.
Braselmann, S, McCormick, F. Bcr and Raf form a complex in vivo via 14-3-3 proteins. EMBO Journal 1995;14:4839–48.
Van Der Hoeven, PC, Van Der Wal, JC, Ruurs, P, Van Dijk, MC, Van Blitterswijk, J. 14-3-3 isotypes facilitate coupling of protein kinase C-zeta to Raf-1: negative regulation by 14-3-3 phosphorylation. Biochemical Journal 2000;345 Pt 2:297–306.
Morrison, DK, Heidecker, G, Rapp, UR, Copeland, TD. Identification of the major phosphorylation sites of the Raf-1 kinase. Journal of Biological Chemistry 1993;268:17 309–16.
Zha, J, Harada, H, Yang, E, Jockel, J, Korsmeyer, SJ. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell 1996;87:619–28.
Brunet, A, Bonni, A, Zigmond, MJ, et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999;96:857–68.
Yaffe, MB. How do 14-3-3 proteins work? Gatekeeper phosphorylation and the molecular anvil hypothesis. FEBS Letters 2002;513:53–7.
Aitken, A, Howell, S, Jones, D, Madrazo, J, Patel, Y. 14-3-3 alpha and delta are the phosphorylated forms of raf-activating 14-3-3 beta and zeta. In vivo stoichiometric phosphorylation in brain at a Ser-Pro-Glu-Lys MOTIF. Journal of Biological Chemistry 1995;270:5706–9.
Dubois, T, Rommel, C, Howell, S, et al. 14-3-3 is phosphorylated by casein kinase I on residue 233. Phosphorylation at this site in vivo regulates Raf/14-3-3 interaction. Journal of Biological Chemistry 1997;272:28 882–8.
Megidish, T, Cooper, J, Zhang, L, Fu, H, Hakomori, S. A novel sphingosine-dependent protein kinase (SDK1) specifically phosphorylates certain isoforms of 14-3-3 protein. Journal of Biological Chemistry 1998;273:21 834–45.
Powell, DW, Rane, MJ, Joughin, BA, et al. Proteomic identification of 14–3–3zeta as a mitogen-activated protein kinase-activated protein kinase 2 substrate: role in dimer formation and ligand binding. Molecular and Cellular Biology 2003;23:5376–87.
Sunayama, J, Tsuruta, F, Masuyama, N, Gotoh, Y. JNK antagonizes Akt-mediated survival signals by phosphorylating 14-3-3. Journal of Cell Biology 2005;170:295–304.
Tsuruta, F, Sunayama, J, Mori, Y, et al. JNK promotes Bax translocation to mitochondria through phosphorylation of 14-3-3 proteins. EMBO Journal 2004;23:1889–99.
Lalle, M, Salzano, AM, Crescenzi, M, Pozio, E. The Giardia duodenalis 14-3-3 protein is post-translationally modified by phosphorylation and polyglycylation of the C-terminal tail. Journal of Biological Chemistry 2006;281:5137–48.
Choudhary, C, Kumar, C, Gnad, F, et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 2009;325:834–40.
Roy, S, McPherson, RA, Apolloni, A, et al. 14-3-3 facilitates Ras-dependent Raf-1 activation in vitro and in vivo. Molecular and Cellular Biology 1998;18:3947–55.
Tzivion, G, Luo, Z, Avruch, J. A dimeric 14-3-3 protein is an essential cofactor for Raf kinase activity. Nature 1998;394:88–92.
Obsil, T, Ghirlando, R, Klein, DC, Ganguly, S, Dyda, F. Crystal structure of the 14–3–3zeta:serotonin N-acetyltransferase complex. a role for scaffolding in enzyme regulation. Cell 2001;105:257–67.
Dumaz, N, Marais, R. Protein kinase A blocks Raf-1 activity by stimulating 14-3-3 binding and blocking Raf-1 interaction with Ras. Journal of Biological Chemistry 2003;278:29 819–23.
Hsu, SY, Kaipia, A, Zhu, L, Hsueh, AJ. Interference of BAD (Bcl-xL/Bcl-2-associated death promoter)-induced apoptosis in mammalian cells by 14-3-3 isoforms and P11. Molecular Endocrinology 1997;11:1858–67.
Zhou, GL, Yamamoto, T, Ozoe, F, et al. Identification of a 14-3-3 protein from Lentinus edodes that interacts with CAP (adenylyl cyclase-associated protein), and conservation of this interaction in fission yeast. Bioscience, Biotechnology and Biochemistry 2000;64:149–59.
Tan, Y, Demeter, MR, Ruan, H, Comb, MJ. BAD Ser-155 phosphorylation regulates BAD/Bcl-XL interaction and cell survival. Journal of Biological Chemistry 2000;275:25 865–9.
Lizcano, JM, Morrice, N, Cohen, P. Regulation of BAD by cAMP-dependent protein kinase is mediated via phosphorylation of a novel site, Ser155. Biochemical Journal 2000;349:547–57.
Datta, SR, Katsov, A, Hu, L, et al. 14-3-3 proteins and survival kinases cooperate to inactivate BAD by BH3 domain phosphorylation. Molecular Cell 2000;6:41–51.
Cahill, CM, Tzivion, G, Nasrin, N, et al. Phosphatidylinositol 3-kinase signaling inhibits DAF-16 DNA binding and function via 14–3–3-dependent and 14–3–3-independent pathways. Journal of Biological Chemistry 2001;276:13 402–10.
Muslin, AJ, Xing, H. 14-3-3 proteins: regulation of subcellular localization by molecular interference. Cellular Signaling 2000;12:703–9.
Brunet, A, Kanai, F, Stehn, J, et al. 14-3-3 transits to the nucleus and participates in dynamic nucleocytoplasmic transport. Journal of Cell Biology 2002;156:817–28.
Rena, G, Prescott, AR, Guo, S, Cohen, P, Unterman, TG. Roles of the forkhead in rhabdomyosarcoma (FKHR) phosphorylation sites in regulating 14-3-3 binding, transactivation and nuclear targetting. Biochemical Journal 2001;354:605–12.
McKinsey, TA, Zhang, CL, Olson, EN. Identification of a signal-responsive nuclear export sequence in class II histone deacetylases. Molecular and Cellular Biology 2001;21:6312–21.
Kumagai, A, Dunphy, WG. Binding of 14-3-3 proteins and nuclear export control the intracellular localization of the mitotic inducer Cdc25. Genes and Development 1999;13:1067–72.
Graves, PR, Lovly, CM, Uy, GL, Piwnica-Worms, H. Localization of human Cdc25C is regulated both by nuclear export and 14-3-3 protein binding. Oncogene 2001;20:1839–51.
Faul, C, Huttelmaier, S, Oh, J, et al. Promotion of importin alpha-mediated nuclear import by the phosphorylation-dependent binding of cargo protein to 14–3–3. Journal of Cell Biology 2005;169:415–24.
LeBron, C, Chen, L, Gilkes, DM, Chen, J. Regulation of MDMX nuclear import and degradation by Chk2 and 14–3–3. EMBO Journal 2006;25:1196–206.
Kim, HH, Abdelmohsen, K, Lal, A, et al. Nuclear HuR accumulation through phosphorylation by Cdk1. Genes and Development 2008;22:1804–15.
O’Kelly, I, Butler, MH, Zilberberg, N, Goldstein, SA. Forward transport. 14-3-3 binding overcomes retention in endoplasmic reticulum by dibasic signals. Cell 2002;111:577–88.
Shikano, S, Coblitz, B, Wu, M, Li, M. 14-3-3 proteins: regulation of endoplasmic reticulum localization and surface expression of membrane proteins. Trends in Cell Biology 2006;16:370–5.
Forrest, A, Gabrielli, B. Cdc25B activity is regulated by 14–3–3. Oncogene 2001;20:4393–401.
Kumagai, A, Yakowec, PS, Dunphy, WG. 14-3-3 proteins act as negative regulators of the mitotic inducer Cdc25 in Xenopus egg extracts. Molecular Biology of the Cell 1998;9:345–54.
Peng, CY, Graves, PR, Thoma, RS, et al. Mitotic and G2 checkpoint control: regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216. Science 1997;277:1501–5.
Rothblum-Oviatt, CJ, Ryan, CE, Piwnica-Worms, H. 14-3-3 binding regulates catalytic activity of human Wee1 kinase. Cell Growth and Differentiation 2001;12:581–9.
Wang, B, Liu, K, Lin, HY, et al. 14–3–3Tau regulates ubiquitin-independent proteasomal degradation of p21, a novel mechanism of p21 downregulation in breast cancer. Molecular and Cellular Biology 2010;30:1508–27.
Hong, HY, Jeon, WK, Bae, EJ, et al. 14-3-3 sigma and 14-3-3 zeta plays an opposite role in cell growth inhibition mediated by transforming growth factor-beta 1. Molecules and Cells 2010;29:305–9.
Rajagopalan, S, Jaulent, AM, Wells, M, Veprintsev, DB, Fersht, AR. 14-3-3 activation of DNA binding of p53 by enhancing its association into tetramers. Nucleic Acids Research 2008;36:5983–91.
Waterman, MJ, Stavridi, ES, Waterman, JL, Halazonetis, TD. ATM-dependent activation of p53 involves dephosphorylation and association with 14-3-3 proteins. Nature Genetics 1998;19:175–8.
Rajagopalan, S, Sade, RS, Townsley, FM, Fersht, AR. Mechanistic differences in the transcriptional activation of p53 by 14-3-3 isoforms. Nucleic Acids Research 2010;38:893–906.
Yang, HY, Wen, YY, Chen, CH, Lozano, G, Lee, MH. 14-3-3 sigma positively regulates p53 and suppresses tumor growth. Molecular and Cellular Biology 2003;23:7096–107.
Yang, HY, Wen, YY, Lin, YI, et al. Roles for negative cell regulator 14–3–3sigma in control of MDM2 activities. Oncogene 2007;26:7355–62.
Morrison, DK. The 14-3-3 proteins: integrators of diverse signaling cues that impact cell fate and cancer development. Trends in Cell Biology 2009;19:16–23.
Tzivion, G, Gupta, VS, Kaplun, L, Balan, V. 14-3-3 proteins as potential oncogenes. Seminars in Cancer Biology 2006;16:203–13.
Wilker, E, Yaffe, MB. 14-3-3 Proteins–a focus on cancer and human disease. Journal of Molecular and Cellular Cardiology 2004;37:633–42.
Chan, TA, Hermeking, H, Lengauer, C, Kinzler, KW, Vogelstein, B. 14–3–3Sigma is required to prevent mitotic catastrophe after DNA damage. Nature 1999;401:616–20.
Wilker, EW, van Vugt, MA, Artim, SA, et al. 14–3–3sigma controls mitotic translation to facilitate cytokinesis. Nature 2007;446:329–32.
Pines, J. Four-dimensional control of the cell cycle. Nature Cell Biology 1999;1:E73–9.
Boutros, R, Lobjois, V, Ducommun, B. CDC25 phosphatases in cancer cells: key players? Good targets? Nature Reviews Cancer 2007;7:495–507.
Donzelli, M, Draetta, GF. Regulating mammalian checkpoints through Cdc25 inactivation. EMBO Reports 2003;4:671–7.
Karlsson, C, Katich, S, Hagting, A, Hoffmann, I, Pines, J. Cdc25B and Cdc25C differ markedly in their properties as initiators of mitosis. Journal of Cell Biology 1999;146:573–84.
Gabrielli, BG, De Souza, CP, Tonks, ID, et al. Cytoplasmic accumulation of cdc25B phosphatase in mitosis triggers centrosomal microtubule nucleation in HeLa cells. Journal of Cell Science 1996;109:1081–93.
Nishijima, H, Nishitani, H, Seki, T, Nishimoto, T. A dual-specificity phosphatase Cdc25B is an unstable protein and triggers p34(cdc2)/cyclin B activation in hamster BHK21 cells arrested with hydroxyurea. Journal of Cell Biology 1997;138:1105–16.
Donzelli, M, Squatrito, M, Ganoth, D, et al. Dual mode of degradation of Cdc25 A phosphatase. EMBO Journal 2002;21:4875–84.
Molinari, M, Mercurio, C, Dominguez, J, Goubin, F, Draetta, GF. Human Cdc25 A inactivation in response to S phase inhibition and its role in preventing premature mitosis. EMBO Reports 2000;1:71–9.
Lee, G, White, LS, Hurov, KE, Stappenbeck, TS, Piwnica-Worms, H. Response of small intestinal epithelial cells to acute disruption of cell division through CDC25 deletion. Proceedings of the National Academy of Sciences USA 2009;106:4701–6.
Toyoshima-Morimoto, F, Taniguchi, E, Nishida, E. Plk1 promotes nuclear translocation of human Cdc25C during prophase. EMBO Reports 2002;3:341–8.
Wang, R, He, G, Nelman-Gonzalez, M, et al. Regulation of Cdc25C by ERK-MAP kinases during the G2/M transition. Cell 2007;128:1119–32.
Hoffmann, I, Clarke, PR, Marcote, MJ, Karsenti, E, Draetta, G. Phosphorylation and activation of human cdc25-C by cdc2–cyclin B and its involvement in the self-amplification of MPF at mitosis. EMBO Journal 1993;12:53–63.
Izumi, T, Maller, JL. Elimination of cdc2 phosphorylation sites in the cdc25 phosphatase blocks initiation of M-phase. Molecular Biology of the Cell 1993;4:1337–50.
Elia, EAH, Rellos, P, Haire, LF, et al. The molecular basis for phosphodependent substrate targeting and regulation of Plks by the Polo-box domain. Cell 2003;115:83–95.
Reinhardt, HC, Yaffe, MB. Kinases that control the cell cycle in response to DNA damage: Chk1, Chk2, and MK2. Current Opinion in Cell Biology 2009;21:245–55.
Chen, MS, Ryan, CE, Piwnica-Worms, H. Chk1 kinase negatively regulates mitotic function of Cdc25A phosphatase through 14-3-3 binding. Molecular and Cellular Biology 2003;23:7488–97.
Davezac, N, Baldin, V, Gabrielli, B, et al. Regulation of CDC25B phosphatases subcellular localization. Oncogene 2000;19:2179–85.
Ogg, S, Gabrielli, B, Piwnica-Worms, H. Purification of a serine kinase that associates with and phosphorylates human Cdc25C on serine 216. Journal of Biological Chemistry 1994;269:30 461–9.
Yang, J, Winkler, K, Yoshida, M, Kornbluth, S. Maintenance of G2 arrest in the Xenopus oocyte: a role for 14–3–3-mediated inhibition of Cdc25 nuclear import. EMBO Journal 1999;18:2174–83.
Peng, CY, Graves, PR, Ogg, S, et al. C-TAK1 protein kinase phosphorylates human Cdc25C on serine 216 and promotes 14-3-3 protein binding. Cell Growth and Differentiation 1998;9:197–208.
Ouyang, B, Li, W, Pan, H, et al. The physical association and phosphorylation of Cdc25C protein phosphatase by Prk. Oncogene 1999;18:6029–36.
Walworth, NC. DNA damage: Chk1 and Cdc25, more than meets the eye. Current Opinion in Genetic Development 2001;11:78–82.
Zhou, BB, Elledge, SJ. The DNA damage response: putting checkpoints in perspective. Nature 2000;408:433–9.
Wang, JY. Cellular responses to DNA damage. Current Opinion in Cell Biology 1998;10:240–7.
Zeng, Y, Forbes, KC, Wu, Z, et al. Replication checkpoint requires phosphorylation of the phosphatase Cdc25 by Cds1 or Chk1. Nature 1998;395:507–10.
Manke, IA, Nguyen, A, Lim, D, et al. MAPKAP kinase-2 is a cell cycle checkpoint kinase that regulates the G2/M transition and S phase progression in response to UV irradiation. Molecular Cell 2005;17:37–48.
Reinhardt, HC, Aslanian, AS, Lees, JA, Yaffe, MB. p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage. Cancer Cell 2007;11:175–89.
Jazayeri, A, Falck, J, Lukas, C, et al. ATM- and cell cycle-dependent regulation of ATR in response to DNA double-strand breaks. Nature Cell Biology 2006;8:37–45.
Lee, J, Kumagai, A, Dunphy, WG. Positive regulation of Wee1 by Chk1 and 14-3-3 proteins. Molecular Biology of the Cell 2001;12:551–63.
Laronga, C, Yang, HY, Neal, C, Lee, MH. Association of the cyclin-dependent kinases and 14-3-3 sigma negatively regulates cell cycle progression. Journal of Biological Chemistry 2000;275:23 106–12.
Bartkova, J, Horejsi, Z, Koed, K, et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005;434:864–70.
Margolis, SS, Walsh, S, Weiser, DC, et al. PP1 control of M phase entry exerted through 14–3–3-regulated Cdc25 dephosphorylation. EMBO Journal 2003;22:5734–45.
Margolis, SS, Perry, JA, Forester, CM, et al. Role for the PP2A/B56delta phosphatase in regulating 14-3-3 release from Cdc25 to control mitosis. Cell 2006;127:759–73.
Mailand, N, Bekker-Jensen, S, Bartek, J, Lukas, J. Destruction of Claspin by SCFbetaTrCP restrains Chk1 activation and facilitates recovery from genotoxic stress. Molecular Cell 2006;23:307–18.
Mamely, I, van Vugt, MA, Smits, VA, et al. Polo-like kinase-1 controls proteasome-dependent degradation of Claspin during checkpoint recovery. Current Biology 2006;16:1950–5.
Peschiaroli, A, Dorrello, NV, Guardavaccaro D, et al. SCFbetaTrCP-mediated degradation of Claspin regulates recovery from the DNA replication checkpoint response. Molecular Cell 2006;23:319–29.
van Vugt, MA, Gardino, AK, Linding, R, et al. A mitotic phosphorylation feedback network connects Cdk1, Plk1, 53BP1, and Chk2 to inactivate the G(2)/M DNA damage checkpoint. PLoS Biology 2010;8:e1000287.
Lodygin, D, Hermeking, H. Epigenetic silencing of 14–3–3sigma in cancer. Seminars in Cancer Biology 2006;16:214–24.
Hu, D, Valentine, M, Kidd, VJ, Lahti, JM. CDK11(p58) is required for the maintenance of sister chromatid cohesion. Journal of Cell Science 2007;120:2424–34.
Petretti, C, Savoian, M, Montembault, E, et al. The PITSLRE/CDK11p58 protein kinase promotes centrosome maturation and bipolar spindle formation. EMBO Reports 2006;7:418–24.
Saurin, AT, Durgan, J, Cameron, AJ, et al. The regulated assembly of a PKCepsilon complex controls the completion of cytokinesis. Nature Cell Biology 2008;10:891–901.
Cornelis, S, Bruynooghe, Y, Denecker, G, et al. Identification and characterization of a novel cell cycle-regulated internal ribosome entry site. Molecular Cell 2000;5:597–605.
Gorin, MA, Pan, Q. Protein kinase C epsilon: an oncogene and emerging tumor biomarker. Molecular Cancer 2009;8:9.
Fantl, WJ, Muslin, AJ, Kikuchi, A, et al. Activation of Raf-1 by 14-3-3 proteins. Nature 1994;371:612–14.
Freed, E, Symons, M, Macdonald, SG, McCormick F, Ruggieri R. Binding of 14-3-3 proteins to the protein kinase Raf and effects on its activation. Science 1994;265:1713–16.
Fu, H, Xia, K, Pallas, DC, et al. Interaction of the protein kinase Raf-1 with 14-3-3 proteins. Science 1994;266:126–9.
Wellbrock, C, Karasarides, M, Marais, R. The RAF proteins take centre stage. Nature Reviews Molecular and Cellular Biology 2004;5:875–85.
Garnett, MJ, Rana, S, Paterson, H, Barford, D, Marais, R. Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization. Molecular Cell 2005;20:963–9.
Rushworth, LK, Hindley, AD, O’Neill, E, Kolch, W. Regulation and role of Raf-1/B-Raf heterodimerization. Molecular and Cellular Biology 2006;26:2262–72.
Noble, C, Mercer, K, Hussain, J, et al. CRAF autophosphorylation of serine 621 is required to prevent its proteasome-mediated degradation. Molecular Cell 2008;31:862–72.
Wan, PT, Garnett, MJ, Roe, SM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004;116:855–67.
Heidorn, SJ, Milagre, C, Whittaker, S, et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell;140:209–21.
Burgering, BM, Medema, RH. Decisions on life and death: FOXO Forkhead transcription factors are in command when PKB/Akt is off duty. Journal of Leukocyte Biology 2003;73:689–701.
Macdonald, A, Campbell, DG, Toth, R, et al. Pim kinases phosphorylate multiple sites on Bad and promote 14-3-3 binding and dissociation from Bcl-XL. BMC Cell Biology 2006;7:1.
Yoshida, K, Yamaguchi, T, Natsume, T, Kufe, D, Miki, Y. JNK phosphorylation of 14-3-3 proteins regulates nuclear targeting of c-Abl in the apoptotic response to DNA damage. Nature Cell Biology 2005;7:278–85.
Bajpai, U, Sharma, R, Kausar, T, et al. Clinical significance of 14-3-3 zeta in human esophageal cancer. International Journal of Biological Markers 2008;23:231–7.
Keshamouni, VG, Michailidis, G, Grasso, CS, et al. Differential protein expression profiling by iTRAQ-2DLC-MS/MS of lung cancer cells undergoing epithelial-mesenchymal transition reveals a migratory/invasive phenotype. Journal of Proteome Research 2006;5:1143–54.
Li, Z, Zhao, J, Du, Y, et al. Down-regulation of 14–3–3zeta suppresses anchorage-independent growth of lung cancer cells through anoikis activation. Proceedings of the National Academy of Sciences USA 2008;105:162–7.
Ostergaard, M, Rasmussen, HH, Nielsen, HV, et al. Proteome profiling of bladder squamous cell carcinomas: identification of markers that define their degree of differentiation. Cancer Research 1997;57:4111–17.
Ferguson, AT, Evron, E, Umbricht, CB, et al. High frequency of hypermethylation at the 14-3-3 sigma locus leads to gene silencing in breast cancer. Proceedings of the National Academy of Sciences USA 2000;97:6049–54.
Iwata, N, Yamamoto, H, Sasaki, S, et al. Frequent hypermethylation of CpG islands and loss of expression of the 14-3-3 sigma gene in human hepatocellular carcinoma. Oncogene 2000;19:5298–302.
Suzuki, H, Itoh, F, Toyota, M, et al. Inactivation of the 14-3-3 sigma gene is associated with 5’ CpG island hypermethylation in human cancers. Cancer Research 2000;60:4353–7.
Umbricht, CB, Evron, E, Gabrielson, E, et al. Hypermethylation of 14-3-3 sigma (stratifin) is an early event in breast cancer. Oncogene 2001;20:3348–53.
Vercoutter-Edouart, AS, Lemoine, J, Le Bourhis, X, et al. Proteomic analysis reveals that 14–3–3sigma is down-regulated in human breast cancer cells. Cancer Research 2001;61:76–80.
Bortner, JD., Das, A, Umstead, TM, et al. Down-regulation of 14-3-3 isoforms and annexin A5 proteins in lung adenocarcinoma induced by the tobacco-specific nitrosamine NNK in the A/J mouse revealed by proteomic analysis. Journal of Proteome Research 2009;8:4050–61.
Li, DQ, Wang, L, Fei, F, et al. Identification of breast cancer metastasis-associated proteins in an isogenic tumor metastasis model using two-dimensional gel electrophoresis and liquid chromatography-ion trap-mass spectrometry. Proteomics 2006;6:3352–68.
Niemantsverdriet, M, Wagner, K, Visser, M, Backendorf, C. Cellular functions of 14-3-3 zeta in apoptosis and cell adhesion emphasize its oncogenic character. Oncogene 2008;27:1315–19.
Lu, J, Guo, H, Treekitkarnmongkol, W, et al. 14–3–3zeta Cooperates with ERBB2 to promote ductal carcinoma in situ progression to invasive breast cancer by inducing epithelial-mesenchymal transition. Cancer Cell 2009;16:195–207.
Danes, CG, Wyszomierski, SL, Lu, J, et al. 14-3-3 zeta down-regulates p53 in mammary epithelial cells and confers luminal filling. Cancer Research 2008;68:1760–7.
Somiari, RI, Somiari, S, Russell, S, Shriver, CD. Proteomics of breast carcinoma. Journal of Chromatography B Analytical Technology Biomedical Life Science 2005;815:215–25.
Zang, L, Palmer Toy, D, et al. Proteomic analysis of ductal carcinoma of the breast using laser capture microdissection, LC-MS, and 16O/18O isotopic labeling. Journal of Proteome Research 2004;3:604–12.
Jang, JS, Cho, HY, Lee, YJ, Ha, WS, Kim, HW. The differential proteome profile of stomach cancer: identification of the biomarker candidates. Oncology Research 2004;14:491–9.
Qi, W, Liu, X, Qiao, D, Martinez, JD. Isoform-specific expression of 14-3-3 proteins in human lung cancer tissues. International Journal of Cancer 2005;113:359–63.
Shoji, M, Kawamoto, S, Setoguchi, Y, et al. The 14-3-3 protein as the antigen for lung cancer-associated human monoclonal antibody AE6F4. Human Antibodies and Hybridomas 1994;5:123–30.
Arora, S, Matta, A, Shukla, NK, Deo, SV, Ralhan, R. Identification of differentially expressed genes in oral squamous cell carcinoma. Molecular Carcinogenesis 2005;42:97–108.
Huber, E, Vlasny, D, Jeckel, S, Stubenrauch, F, Iftner, T. Gene profiling of cottontail rabbit papillomavirus-induced carcinomas identifies upregulated genes directly involved in stroma invasion as shown by small interfering RNA-mediated gene silencing. Journal of Virology 2004;78:7478–89.
Hermeking, H, Lengauer, C, Polyak, K, et al. 14-3-3 sigma is a p53-regulated inhibitor of G2/M progression. Molecular Cell 1997;1:3–11.
Aprelikova, O, Pace, AJ, Fang, B, Koller, BH, Liu, ET. BRCA1 is a selective co-activator of 14-3-3 sigma gene transcription in mouse embryonic stem cells. Journal of Biological Chemistry 2001;276:25 647–50.
Henrique, R, Jeronimo, C, Hoque, MO, et al. Frequent 14-3-3 sigma promoter methylation in benign and malignant prostate lesions. DNA and Cell Biology 2005;24:264–9.
Kang, GH, Lee, S, Kim, WH, et al. Epstein-barr virus-positive gastric carcinoma demonstrates frequent aberrant methylation of multiple genes and constitutes CpG island methylator phenotype-positive gastric carcinoma. American Journal of Pathology 2002;160:787–94.
Gasco, M, Bell, AK, Heath, V, et al. Epigenetic inactivation of 14-3-3 sigma in oral carcinoma: association with p16(INK4a) silencing and human papillomavirus negativity. Cancer Research 2002;62:2072–6.
Gasco, M, Sullivan, A, Repellin, C, et al. Coincident inactivation of 14–3–3sigma and p16INK4a is an early event in vulval squamous neoplasia. Oncogene 2002;21:1876–81.
Kaneuchi, M, Sasaki, M, Tanaka, Y, et al. Expression and methylation status of 14-3-3 sigma gene can characterize the different histological features of ovarian cancer. Biochemical and Biophysical Research Communications 2004;316:1156–62.
Uchida, D, Begum, NM, Almofti, A, et al. Frequent downregulation of 14-3-3 sigma protein and hypermethylation of 14-3-3 sigma gene in salivary gland adenoid cystic carcinoma. British Journal of Cancer 2004;91:1131–8.
Bhawal, UK, Tsukinoki, K, Sasahira, T, et al. Methylation and intratumoural heterogeneity of 14-3-3 sigma in oral cancer. Oncology Report 2007;18:817–24.
Kunze, E, Schlott, T. High frequency of promoter methylation of the 14-3-3 sigma and CAGE-1 genes, but lack of hypermethylation of the caveolin-1 gene, in primary adenocarcinomas and signet ring cell carcinomas of the urinary bladder. International Journal of Molecular Medicine 2007;20:557–63.
Zhu, F, Xia, X, Liu, B, et al. IKKalpha shields 14–3–3sigma, a G(2)/M cell cycle checkpoint gene, from hypermethylation, preventing its silencing. Molecular Cell 2007;27:214–27.
Urano, T, Saito, T, Tsukui, T, et al. Efp targets 14-3-3 sigma for proteolysis and promotes breast tumour growth. Nature 2002;417:871–5.
Chan, TA, Hermeking, H, Lengauer, C, Kinzler, KW, Vogelstein, B. 14–3–3Sigma is required to prevent mitotic catastrophe after DNA damage. Nature 1999;401:616–20.
Dellambra, E, Golisano, O, Bondanza, S, et al. Downregulation of 14–3–3sigma prevents clonal evolution and leads to immortalization of primary human keratinocytes. Journal of Cell Biology 2000;149:1117–30.
Fujiwara, T, Bandi, M, Nitta, M, et al. Cytokinesis failure generating tetraploids promotes tumorigenesis in p53-null cells. Nature 2005;437:1043–7.
Shi, Q, King, RW. Chromosome nondisjunction yields tetraploid rather than aneuploid cells in human cell lines. Nature 2005;437:1038–42.
Hanahan, D, Weinberg, RA. The hallmarks of cancer. Cell 2000;100:57–70.
Luo, J, Solimini, NL, Elledge, SJ. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 2009;136:823–37.
Maxwell, SA, Li, Z, Jaya, D, et al. 14–3–3zeta mediates resistance of diffuse large B cell lymphoma to an anthracycline-based chemotherapeutic regimen. Journal of Biological Chemistry 2009;284:22 379–89.
Guweidhi, A, Kleeff, J, Giese, N, et al. Enhanced expression of 14–3–3 sigma in pancreatic cancer and its role in cell cycle regulation and apoptosis. Carcinogenesis 2004;25:1575–85.
Neupane, D, Korc, M. 14–3–3sigma Modulates pancreatic cancer cell survival and invasiveness. Clinical Cancer Research 2008;14:7614–23.
Wang, B, Liu, K, Lin, HY, et al. 14–3–3Tau regulates ubiquitin-independent proteasomal degradation of p21, a novel mechanism of p21 downregulation in breast cancer. Molecular and Cell Biology; 30:1508–27.
Wang, B, Yang, H, Liu, YC, et al. Isolation of high-affinity peptide antagonists of 14-3-3 proteins by phage display. Biochemistry 1999;38:12 499–504.
Masters, SC, Fu, H. 14-3-3 proteins mediate an essential anti-apoptotic signal. Journal of Biological Chemistry 2001;276:45 193–200.
Nguyen, A, Rothman, DM, Stehn, J, Imperiali, B, Yaffe, MB. Caged phosphopeptides reveal a temporal role for 14-3-3 in G1 arrest and S-phase checkpoint function. Nature Biotechnology 2004;22:993–1000.